FDAnews
www.fdanews.com/articles/72730-anges-mg-vical-conclude-licensing-agreement

AnGes MG, Vical Conclude Licensing Agreement

May 26, 2005

AnGes MG announced that it concluded a licensing agreement with U.S. company Vical on the same day. Under the terms of the agreement, AnGes MG will exclusively use Vical's patented non-viral gene delivery technology worldwide. Using the technology, AnGes MG aims to develop and commercialize HGF (Hepatocyte Growth Factor) gene medicine for peripheral vascular disease and ischemic heart disease.

()a href="http://www.japancorp.net/Article.Asp?Art_ID=10150" target="_blank">Japan Corporate News Network